UK Markets closed
NIKKEI 225
26,547.05 +119.40 (+0.45%) HANG SENG
19,950.21 +51.44 (+0.26%) CRUDE OIL
113.64 +3.15 (+2.85%) GOLD FUTURES
1,824.70 +16.50 (+0.91%) DOW
32,223.51 +26.85 (+0.08%) BTC-GBP
24,155.04 -553.00 (-2.24%)
Clinigen Group Plc (CLIN.L)
LSE - LSE Delayed price. Currency in GBp
Add to watchlist
At close: 05:15PM BST
| Previous close | 924.00 |
| Open | 924.00 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 924.00 - 925.00 |
| 52-week range | 9.25 - 948.05 |
| Volume | |
| Avg. volume | 1,679,225 |
| Market cap | 1.234B |
| Beta (5Y monthly) | 1.47 |
| PE ratio (TTM) | 41.48 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 0.08 (0.82%) |
| Ex-dividend date | 02 Dec 2021 |
| 1y target est | N/A |
- Business Wire
Form 8.5 (EPT/NON-RI) - CLINIGEN GROUP PLC
LONDON, March 08, 2022-- FORM 8.5 (EPT/NON-RI)
- Business Wire
Humanigen Launches Managed Access Program for Lenzilumab
BURLINGAME, Calif. & DUBLIN & LONDON, February 10, 2022--Humanigen, Inc. (Nasdaq: HGEN), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,’ announced today that lenzilumab is now available for certain hospitalized COVID-19 patients through its newly-launched Managed Access Program ("LenzMAP™"). Clinigen Group plc ("Clinigen"), a global pharmaceutical Services and Products company, is implementing the program. Lenzilumab
© 2022 Yahoo. All rights reserved.
